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What is known of the pathogenesis and pathophysiology of the onset of only typical 
migraine is discussed. This includes familial hemiplegia headaches and migraine with or without 
aura. This does not include common tension headaches or other common headaches not involved 
in similar pathogenesis to the trigeminovascular pathological pathways causing migraine. The 
format is a general discussion on current theories on migraine pathophysiology, current 
pharmaceutical therapies and statistics on typical migraine. 
Introduction:  
“A masters student in Biomedical Sciences visits his professors during office hours, not 
yet eager to go over course material (although certainly soon) but to make them aware that he 
suffers from acute episodes of migraine which often become debilitating and force him to miss 
class. He lays out the details of this condition to his instructors in hopes that they are willing 
to work with him should interference with coursework arise. The student, in order to earn his 
master’s degree, decides to investigate the problem that affects him and millions of other 
migraineurs in order to help other migraineurs and non-migraineurs alike improve their 
understanding of this often overlooked, highly prevalent class VII disability.” 
Migraine is an episodic headache disorder affecting 38 million people in the U.S.; 8.6% 
of males and 17.5% of females (Doulberis, Michael et al) and 324 million worldwide according 
to the World Health Organization report on the Global Burden of Disease. Migraine sufferers, 
often referred to as “migraineurs”, report varying degrees of pain, recurrence, symptoms and 
associated causes of their migraine attacks (Davidoff). Each migraineur’s experience with 
migraine is different and the degree to which it inhibits daily functioning varies significantly. In 
the same report, the WHO rates severe migraine, along with quadriplegia, psychosis, and 
dementia, as one of the most disabling chronic disorders. (Michael) It is also one of the top three 
overlooked prevalent conditions in the world, right along with anaemia and hearing loss. Health 
care for patients with migraine cost nearly $11 billion per year to directly treatment and nearly 
$12 billion in indirect costs for missed work hours and other expenses (Loder). Due to this 
detriment to our society, this review aims to describe what migraine is, current treatment options 
and future options according to research. 
Even though migraine is one of the oldest disorders known to man, its pathophysiology 
and pathogenesis has never been fully understood. The condition was prevalent in ancient 
Egyptian society, dated in records as early as 1200 B.C. (Mandal). Hippocrates referred to the 
ocular disturbances of scintillating scotoma in some of his works, describing the moments of 
relief from migraine attacks after intense pain and episodes of emesis. Credit for the discovery of 
migraine is given to Aretaeus of Cappadocia, who described in the second century further 
clinical symptoms such as unilateral pain in the cranium (Mandal). Modern research on the topic 
has led to better experiments and drug development for migraine sufferers. However, discussed 
later in this review, there is only one drug on the market currently approved by the FDA 
targeting specific neuropeptides related to migraine development. 
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 No proposed mechanism fully encompasses what 
occurs during a migraine. However, the majority of 
findings agree on these assumptions: 
1. Predisposition for migraine exists in 
familial lines, suggesting the condition is a 
multi-genic polymorphism and complex 
interactions occur at the level of gene 
expression. 
2. The mechanism which causes migraine is 
not the same between every migraineur as 
only about one-third of sufferers 
experience aura; the frequency of attacks, 
magnitude of pain and response to 
treatment varies between individuals. 
3. Most research accepts the four phase structure to explain pathophysiology but it 
should be mentioned that there is often overlapping and variability (Charles). 
4. The vascular theory, neurogenic theory and neuroinflammatory theory all likely 
contribute to describing the complexity of migraine pathophysiology. Other 
propositions such as the sino-rhinogenic pathway also warrant further study. 
Vascular Theory 
Three primary theories on the pathological mechanism of migraine exist and it is 
considered that all three play some role in the mechanism of migraine attacks. The oldest is the 
vascular theory, first observed by Harold G. Wolff in the 1950s, observing that cerebral 
vasoconstriction of blood vessels with cortical spreading depression leads to a depolarization 
event of neurons across grey matter of cortical regions of the brain which can cause an ocular 
deficiency referred to as aura. Aura is seizure-like symptoms of temporary hallucinations seen as 
blind-spots in combination with visualization of scintillating, jagged lights and lines that fill 
portions of the visual space. Aura is followed by a compensatory mechanism of vasodilation of 
these blood vessels, leading to a throbbing pain experienced shortly after the migraine onset. 
Today, most theories agree in the premonitory phase, vasoactive peptides are released from 
primary sensory nerve terminals innervating meningeal blood vessels. They activate perivascular 
trigeminal nerves and cause dilatation of arteries in meninges as well as perivascular 
inflammation and extravasation of plasma proteins. First-order neurons terminate in the 
trigeminal nucleus caudalis in the brain stem. They activate second-order neurons that ascend to 
the thalamus and from there, third-order neurons project to higher cortical centers. If 
uninterrupted, this process causes pain and can lead to hyperalgesia and allodynia, both 
hallmarks of prolonged migraine attacks (Goadsby). 
Neurologist Harold G. Wolff led pioneering experiments to come up with a 
comprehensive set of assumptions about migraine symptoms in 1963 (Davidoff). Wolff 
concluded from his studies that symptoms were strongly associated with vascular problems. His 
three assumptions: 1. visual auras transiently regressed when cerebra vasodilation was induced 
by amyl nitrate administration or by inhalation of 10% CO2 and 90% O2 (Marcussen RM). 2. 
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During the headache, the amplitude of the superficial temporal artery pulse increased, and 
concomitantly, the throbbing or pounding quality of the pain migraine correlated with these 
increases in pulse amplitude (Davidoff). 3. Ergotamine, which reduced the pulsations of the 
superficial temporal artery, relieved the migraine pain (Graham). Although novel findings, these 
assumptions do not come without scrutiny. The problem with Wolff’s studies was that he had no 
way of studying cerebral blood flow directly so everything was based indirectly on clinical 
evidence. They also fail to address the pathogenesis of triggering (chemical) events of vascular 
dysfunction. Therefore, this theory cannot act alone in describing migraine pathophysiology. 
This is where the neurovascular theory is introduced. 
Neurovascular Theory 
The neurovascular theory is based on the observation of an event described during MRI 
scans called cortical spreading depression, often abbreviated SD. During SD, neural inhibition 
due to a cascade of potential chemical mediators and a pro-inflammatory response cause 
sporadic and pulsating spread of neuronal depolarization across cortical regions. SD traverses the 
cerebral cortex grey matter at a velocity of 2-5 mm/min. This process could either directly or 
indirectly activate the aura phase and trigeminal afferent projections to brain areas associated 
with nociceptive processing (Parsons), which in turn cause headache. During this event, effects 
on perivascular nerve activity from SD results in the release of substances such as calcitonin 
gene related peptide, neurokinin A, substance P, and NO. These substances produce blood vessel 
dilation, protein extravasation and sterile inflammation, stimulating the trigeminocervical 
complex. The vascular theory describes that high levels of extracellular potassium is present in 
the cortical regions of the brain, leading to reduced blood flow and possible trigger of the 
compensatory action of vasodilatation phase. This is thought to be the final event leading to the 
onset of pain in the cerebrum. 
Neuroinflammation Theory 
The neuroinflammation theory focuses specifically on the chemical mediators that act on 
vaso- and nociceptive receptors in the brain. The neuroinflammation theory describes the role of 
neuropeptide release in cerebral regions that ultimately cause pain as described in previous 
theories, such as neurokinin, SP and CGRPs. These peptidyl signaling molecules have major 
effects on the function of the trigeminal nerve, which is one of twelve cranial nerves that 
influences feeling and homeostasis mechanisms for the cranial region in humans. This theory is 
one of the least understood by researchers because clinical observations in humans are hard to 
test. Mouse and culture studies are the best approaches to researching this topic until the role of 
individual signaling molecules is better understood. In addition, most drugs developed for 
prevention and treatment are based on the activation or deactivation of neuronal cells affected by 
these molecules. 
Substance P and calcitonin gene related peptide are two neuromodulators with receptors 
throughout the central nervous system that play some role in the cascading events of migraine. 
Substance P is a modulator of pain and nociception. It antagonistically binds to neurokinin-1 
receptors. In mouse studies, it shows signs of vasoconstrictor properties along with 
antidepressant and anxiolytic properties. However, evidence is lacking on the impairment of 
substance P-mediated neurotransmission in depression and CSF studies in depressed patients are 
not agreed upon. Calcitonin gene-related peptide, CGRP, is a longer vasoactive and nociceptive 
regulatory peptide located in both central and peripheral neurons (Edvinsson). It has been well 
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established that CGRP is a potent vasodilator and it is thought that its physiological role is to 
help control blood pressure. It may also be involved in olfactory, auditory, vision, and pain 
pathway, and contribute to learning, feeding and other behaviors (Keiffer). CGRP inhibits T-cell 
proliferation by inhibiting IL-2 production while stimulating the production of cytokines such as 
IL-6, IL-10 and TNF. In macrophage, it inhibits antigen presentation and other macrophage 
functions inducing phagocytosis (Van Der Kleij). CGRP antagonistic antibodies are being 
produced to test efficacy in reducing migraine attacks for some individuals. The drug Erenumab 
is the only FDA approved CGRP-receptor antagonist on the market in the US. 
Aspects of all three theories work to describe the mechanism involved in migraine. With 
all three theories in mind, the goal in migraine research is to alter an event in the cascading 
pathophysiology to eradicate symptoms of migraine. There are a select number of drugs which 
aim to do this, while most drugs taken for the treatment of migraine have to do with blocking 
nociceptive pathways occurring only in the migraine phase. 
Sinus Hypoxic Nitric Oxide Theory 
A fourth theory on the sino-rhinogeric pathway as a possible pathogenesis for migraine 
has shown warrant for study in the near future. Besides substance P and CGRP, nitric oxide is a 
class IV neurotransmitter produced from glycerol trinitrate to work as a vasodilator. Starting 
from the known trigeminal nociceptive impulse in the migraine, two main peripheral trigeminal 
nerve activating mechanisms may induce migraine. First the nerve endings of the nasal mucosa 
which are directly stimulated by diffuse paranasal sinus nitric oxide are indirectly stimulated by 
vasoactive substances released by antidromic activation of the nerve, parasympathetic efferent of 
the nerve and sterile neurogenic inflammation. Secondly, the perivascular nerve of nasal mucosal 
and the meningeal blood vessels are directly stimulated by either diffuse paranasal sinus nitric 
oxide or by shear stress mediation. Moreover, sino-rhinogenic impulses may mediate to 
disruption of inhibitory sensitization modulated of sensory input and cause sensory 
hyperexcitability. In addition neuronal stimulation proposed by some migraine hypotheses could 
also give rise to migraine headache when the sino-rhinogenic vulnerable factors induce the 
migraine pathophysiology. (Bandara). Bandara suggests that migraineurs should have a 
comprehensive sino-rhinological examination performed as a standard surgical and medical 
management of migraine that links with the sinus hypoxic nitric oxide theory may restore the 
hypoxic state or reduce or remove the paranasal sinus nitric oxide diffusing surface. 
 
Symptoms 
Ocular disturbances such as aura, described also as scintillating scotoma, hypersensitivity 
to light, sound and smell (Noseda); nausea, and a number of autonomic, cognitive, emotional and 
motor disturbances (Olesen) are noted as main disturbances reported by migraineurs. Noseda and 
Burstein characterize much of the throbbing pain associated with migraine to be a result of 
dysfunction of the trigeminovascular pathway, suggesting there is a strong connection between 
neurogenic and vascular pathways that lead to the throbbing pain. Other lesser known symptoms 
that are linked to premonitory phase (Griffin et. al.) changes include: episodic depression, 
anxiety, craving for food, insomnia and hyper- or hypoactivity. Many migraineurs report these 
phenomena preceding the actual aura or pain that comes with a migraine attack. Mild numbness 
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and tingling of extremities, allodynia, nausea, emesis and other underlying symptoms like 
hyperactivity vary in characterization between migraineurs but are often attributed to stimulation 
of dopaminergic and serotonergic pathways. These pathways are either an inciting cause or are 
stimulated downstream by trigeminovascular changes. Little is known on the exact mechanism 
behind this but the efficacy of triptans and antidepressants as migraine prophylactics identifies 
another connection in this complex disorder. 
Triggers of Attack 
 Of what little is truly understood on the underlying mechanism of the pathophysiology is 
the same in the case of pathogenesis. Many migraineurs believe they have identified foods in 
their diet containing particular compounds as tyrosine (a vasodilator), mood disorders such as 
depression and mania linked to serotonergic imbalances, and bright lights or sounds are often 
identified as triggers in patients. No studies have shown significant correlations between these 
pathways but it is early to make a definitive statement. It is possible that these assumed triggers 
can be explained by the behavior observed in the premonitory phase when the onset of an attack 
is inevitably forthcoming. However, documented internal and external triggers in those at a 
genetic predisposition for migraine include, broadly: stress, hormonal fluctuations, sleep 
disturbances, meal skipping or sensory overload (Kelman, Levy). All of these factors are 
believed to have the ability to alter the excitability capable of activating cascading 
pathophysiological pathways of the trigeminovascular system (Coppola, Pietrobon, Stankewitz). 
Some link their triggering events to stress due to overexhaustion, sleep deprivation and other 
factors. 
The same often occurs with food. Many migraneurs believe they are allergic to certain 
ingredients in food that trigger their migraine so they avoid certain foods they believe to contain 
those ingredients, such example as chocolate or alcoholic beverages. Chocolate is the most 
frequent food cited by patients as a trigger and is listed by many authors as a major precipitant of 
migraine attacks (Dalton,Hanington, et al.). A hypothesis is that the potent vasoactive amine 
beta-phenylethylamine, also found in some fermented foods, is the chemical responsible for 
inducing headache attacks (Schweitzer). Chocolate also contains a complex mixture of other 
compounds such as phenolic compounds, which includes: tyramine, octopamine and serotonin 
(Schweitzer).  However, these studies are far outdated and one possible conclusion is that 
cravings for chocolate or other food/beverage is likely an unrecognized prodrome as the attack 
had already started, patients are not aware because they have not reached the aura or headache 
phase (Davidoff). The common conclusion on dietary triggers in migraine is that compounds 
identified as vasodilators or vasoconstrictors may play a role in pathogenesis but not enough data 
is available to make a definitive statement. 
Aura 
 Aura, also recognized as scintillating scotoma, is the first sign of a migraine attack as a 
prodrome for about one-third of migraineurs (Shams, Plant). When an aura occurs, the first sign 
is typically a small “blind-spot” that occurs at or near the focal point of the visual field. This spot 
is described as less than that of a spot, rather a lack of perception of anything at that particular 
point in the visual field. Within the next five to ten minutes, the spot begins to expand and take 
the shape of a curvature with scintillating zig-zag lines and shapes. This shape morphs, expands 
and sometimes multiplies in the visual field for 5-45 minutes and then settles as blurriness of the 
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peripheries before the visual field returns to normal. Residual blind spots may persist in the field 
of vision and hypersensitivity to light may exacerbate these effects. The widely accepted theory 
is that cortical spreading depression (SD), is a wave of neuronal hyperactivity followed by 
cortical depression which accounts for the aura (Lauritzen, Ataya). A study by Hadjikhani and 
colleagues reveals that migraine aura is in fact neuronal, likely evoked by aberrant firing of 
neurons and related cellular elements characteristic of SD and is not evoked by ischemic 
conditions (Hadjikhani). 
It is believed that this dysfunction has associations with the ophthalmic division (CNV-1) 
of the trigeminal nerve (CNV) as the trigeminal nerve plays other key roles in the mediation of 
migraine at other stages of the cascading effects. Typical migraine headache with aura has not 
been reported following enucleation or evisceration of the eye which suggests the visual 
disturbances experienced originate at the visual cortex (Gupta). The conclusion of one study 
suggests that migrainous scintillating scotoma and headache result from mechanical deformation 
of corneo-scleral envelope. No drug has been developed to stop an aura once begins but 
preventative migraine therapy drugs that target to lessen the occurrence of migraines can also 
lower the occurrence of migraine associated auras.  
Genetic 
The role of genetics in identifying individuals with disease or at a predisposition for a 
disorder such as migraine must be taken into consideration. Although characteristics for migraine 
seem to be familial, genome-wide association studies have not yet identified any genetic 
alterations with large effect sizes (Nyholt). A total of 38 genomic loci have been associated with 
migraine in population studies (Gormey). Migraine is caused by a complex interaction between 
genetic and environmental risk factors. The disorder phenotype co-segregates with mutations in 
genes commonly cited which include: CACNA1A, ATP1A2, SCN1A, KCNK18 and NOTCH3 
(Rainero). The analysis of genotype-phenotype correlation in migraineurs has several 
confounding factors and thus far, only polymorphisms of the MTHFR gene have shown an effect 
on migraine phenotype (Rainero). More studies need to be conducted to clarify the complex 
interactions of polymorphisms with phenotypic expression.  
Drugs - Treatment 
Triptans 
 Triptans are serotonin 5-hydroxytryptamine (5-HT1B/1D) receptor antagonists that have 
had the most effective prophylactic response in the treatment of moderate to severe migraine. 
Triptans are not effective in the aura phase of migraine and are most effective when taken within 
1-2 hours of the onset of the headache phase and before allodynia for the most effective 
treatment. Triptans were originally thought to cause cranial vasoconstriction to stop headache 
pain by action at postsynaptic 5-HT1B receptors on the smooth muscle cells of blood vessels 
(Loder). The new hypothesis is that triptans bind to presynaptic 5-HT1D receptors on nerve 
terminals and on dorsal horn, blocking release of neurotransmitters that activate second-order 
neurons that otherwise reach the thalamus (Levy). The idea is that they facilitate descending pain 
inhibition systems in the central nervous system. It is estimated that triptans are effective in 60% 
of non-responders to NSAIDS (Linde) and there is no significant difference in efficacy between 
the seven types of triptans. Triptan drugs are approved for both oral and subcutaneous 
Typical Migraine 




administration. Patients have the option of subcutaneous injection, which is especially useful 
when unable to keep down a pill due to vomiting. 
 Other specific methods for pharmaceutical treatment of migraine include ergotamine (an 
ergot alkaloid) and nasal dihydroergotamine (DHE), which both show analgesic effects. Often 
times, ergotamine drugs will be paired with caffeine as a powerful cranial vasoconstrictor. This 
treatment option is typically reserved for patients when the individual shows little or no response 
to triptans as the primary treatment option (Silberstein). Oral administration is typical but 
epidurals are available when nausea and vomiting are a risk. The nasal DHE is typically reserved 
as a third option to treat moderate or severe migraine when other options do not show efficacy. 
This medication can be administered intranasally or through IV injection. These treatment 
options are not uncommon because the onset of a migraine is best treated early using a high dose 
on the therapeutic ladder to try to combat nociceptive pain receptors early in the pathogenesis.  
 Non-specific migraine medications include simple analgesic approaches and subsequent 
combination analgesic therapies if pain persists. Analgesics such as aspirin, ibuprofen or 
paracetamol are usually first choice for patients who perceive a mild migraine attack. Reviews 
show that 1000mg paracetamol in combination with 10mg metoclopramide has the same short 
term efficacy as 100mg sumatriptan on mild attacks (Derry). This same data shows that aspirin is 
well tolerated at up to 1000mg and non-steroidal anti-inflammatory drugs such as naproxen, 
diclofenac, etc. have been shown to have similar efficacy with mild attacks. Combinations of 
acetaminophen, aspirin and caffeine under drug names like Excedrin are often the first choice in 
treating acute migraine. It is safe to take simple and combinational analgesics within label 
dosage guidelines along with sumatriptan due to their differences in mode of action. 
Preventative Treatments 
 Drugs that show efficacy in preventing migraine nociception and/or frequency of attacks 
are often prescribed to migraineurs who deem it necessary to combat migraines to maintain daily 
functioning. Patients who try preventative therapies should know that these drugs may not stop 
all attacks or prevent the aura phase. However, two-thirds of patients can expect a 50% reduction 
in headache frequency (Moja) and that treatment drugs may be necessary when an attack does 
occur. These factors should be hep doctor and patient determine if preventative therapy is 
beneficial: 
1. Migraine attacks become debilitating >2 per month, having a significant impact on 
lifestyle. 
2. Treatment drugs are not fully effective and are at risk of overuse. 
3. Patient shows desire to try pharmacological steps in preventing migraine attacks. 
Beta-Adrenergic Blockers 
 Beta blockers are a widely used class of preventative treatment for migraine and their 
interaction with the events of migraine are not understood. A study of beta blockers and 
riboflavin by Peter Sandor and colleagues aimed to investigate the influence of pharmacological 
treatments on the intensity dependence of auditory evoked potentials in migraine. The rationale 
is that patients with migraine show abnormal cortical information processing and decreased brain 
mitochondrial energy reserve. Both of these are relevant for study of migraine pathogenesis and 
could be modified with drug therapy. Results from treatment with beta blockers showed the 
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intensity dependence of the auditory evoked cortical potentials was significantly decreased 
(before: 1.66 ± 1.02 μV/10 dB; after: 0.79 ± 1.06 μV/10 dB, P=.02). The decrease in intensity 
dependence was correlated significantly with clinical improvement (r=.69, P=.02). There was no 
change in intensity dependence after riboflavin treatment (before: 1.80 ± 0.81 μV/10 dB; after: 
1.56 ± 0.83 μV/10 dB, P=.39), although the majority of patients showed improvement. The 
conclusion is that beta blockers show a significant decrease in intensity of migraine, especially 
when combined with a B vitamin like B12 (riboflavin). The use of beta blockers shows strong 
efficacy without increasing central nervous system side effects in use as a migraine preventative. 
Antidepressants 
 Tricyclic antidepressants are the top choice in migraine prophylaxis over SSRIs, SNRIs 
and MAOIs likely because of their low cost and availability. In limited clinical trials, 
amitriptyline was shown to work as well as propanolol as an effective treatment for migraines 
(Silberstein) with medication overuse, insomnia, tension type headache and migraine with 
depression (Miller). The second option for antidepressant treatment is a selective serotonin 
reuptake inhibitor which can help alleviate comorbid depression in migraineurs although there is 
no proof of the efficacy of this route (Ozyalcin). Other antidepressants such as venlafaxine, a 
serotonin-norepinephrine reuptake inhibitor has proven more effective than placebo in reducing 
the frequency of attacks in dosages of 150mg (Chronicle). 
Anti-Epileptics (AEDs) 
 A Cochrane Review of AEDs showed that migraineurs were more than twice as likely to 
experience a 50% reduction in the frequency of their migraines versus placebo (Bussone). This 
includes drugs like valproate, topiramate and gabapentin. Topiramate is a sulfamate-substituted 
monosaccharide, related to fructose. It is rapidly absorbed (peak plasma concentrations about 2 
hours after intake) with a high bioavailability (81% to 95%) (May). Topiramate may not have an 
impact on a specific channel or subtype, rather, it has effects on multiple channel types. It is 
known to block voltage gated-ion dependent sodium channels and calcium channels (Zona) and 
inhibits excitatory glutamate pathway while at the same time enhancing inhibition of GABA and 
carbonic anhydrase activity (Shank). Valproate shows similar modes of action and is often 
preferred for patients with comorbid depression or bipolar. Gabapentin is shown to be less 
efficacious than topiramate and valproate (Miller). The mode of action of these drugs in the role 
of migraine pathophysiology is still unclear. 
CGRP antagonist 
 A young but promising class of drugs used to prevent migraine are calcitonin gene-
related peptide antagonists developed as antibodies to block calcitonin receptors in the central 
nervous system. CGRP influences neuronal modulation of pain and vascular activity. They are 
found throughout the body but in the pathophysiology of migraine, they are facilitated particular 
in the dorsal root and trigeminal ganglions (Edvinsson). Two subsets of CGRP therapies exist. 
Known pharmacologically as “-gepants” (Hershey), the first is a CGRP antagonist, inhibiting the 
production of CGRP in the dorsal root and trigeminal ganglions. Four monoclonal antibodies 
(erenumab) are developed to target CGRP receptor (erenumab) or targeting these peptides 
directly (eptinezumab, fremanezumab and galacanezumab).. In phase 3 clinical trials, 
fremanezumab groups reduced baseline number of migraine attacks by more than two greater 
than placebo, showing marginal but meaningful efficacy (Hershey). It is relevant to include that 
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CGRPs are found throughout the body and their exact function is not understood. The alteration 
of long term interactions of CGRP antagonists with organ systems is unknown. 
Conclusion 
 Since the original characterizations of typical migraine from the eras of Hippocrates to 
Aretaeus of Cappadocia to Harold G. Wolff and beyond, we now know much more about the 
pathophysiology and clinical symptoms with key players in their respective roles. Despite the 
efforts of current research, the complexity of the disorder continues to be just as prevalent issue 
as anemia and hearing loss in our modern world. Understanding the detriment that this disorder 
can have on the individual is something that employers, employees, family members and others 
need to be aware of in order to accommodate for lost time and participation when a migraine 
attack occurs. The goal of this review was to compile information to help with understanding the 
major parts involved with the disorder and what can be done to better treat it. The best 
conclusion to be made is that no one drug may be the end-all answer for every individual. The 
goal is that one day genetic therapies could conduct target gene therapies for polymorphisms 
identified in familial migraine symptoms to potentially deal with the gene expression level. More 
studies in the areas of gut-brain axis may eventually paint a picture of the overall interactions of 
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